PC(16:0/18:1(9Z))

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: PC(16:0/18:1(9Z))
• 英文别名: 2-[[(2R)-3-hexadecanoyloxy-2-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
• 化学式: C42H83NO8P+
• 分子量: 761.1
• InChiKey: WTJKGGKOPKCXLL-VYOBOKEXSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  13.7
• 重原子数：
  52
• 可旋转键数：
  41
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSITIONS LIPIDIQUES POUR L'ADMINISTRATION DE COMPOSÉS AGONISTES DE STING ET LEURS UTILISATIONS
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2021216572A1

  公开（公告）日：2021-10-28

  The present disclosure provides lipid compositions comprising lipid particles (e.g., lipid nanodiscs), wherein the lipid particles (e.g., lipid nanodiscs) comprise a STING agonist amphiphile conjugate, a phospholipid and a PEG-lipid. The compositions are used in methods to induce or promote immune responses, such as immune responses useful for the treatment of cancer or infectious disease.

  本公开提供了包含脂质粒子（例如脂质纳米盘）的脂质组合物，其中脂质粒子（例如脂质纳米盘）包含STING激动剂两亲分子共轭物、磷脂和PEG-脂质。该组合物用于诱导或促进免疫反应，例如用于治疗癌症或传染病的免疫反应。
• METHOD FOR PRODUCING GELATINOUS COMPOSITION
  申请人：KANEKA CORPORATION

  公开号：EP3922315A1

  公开（公告）日：2021-12-15

  The objective of the present invention is to provide a method for easily producing a gelatinous composition that contains a phospholipid and is excellent in an emulsion stability, a method for easily producing an emulsified composition excellent in a use feeling and an emulsion stability, a gelatinous composition excellent in an emulsion stability, and an emulsified composition excellent in a use feeling and an emulsion stability. The method for producing a gelatinous composition according to the present invention is characterized in comprising the steps of dissolving a phospholipid and a cyclic lipopeptide biosurfactant in a polyol or a mixed solvent of water and a polyol to obtain a surfactant solution, and mixing an oily ingredient with the surfactant solution to obtain the gelatinous composition, wherein a mass ratio of the cyclic lipopeptide biosurfactant to the phospholipid in the gelatinous composition is 0.25 or more.

  本发明的目的是提供一种易于生产含有磷脂且乳化稳定性极佳的胶状组合物的方法、一种易于生产使用感和乳化稳定性极佳的乳化组合物的方法、一种乳化稳定性极佳的胶状组合物以及一种使用感和乳化稳定性极佳的乳化组合物。根据本发明生产胶状组合物的方法，其特征在于包括以下步骤：将磷脂和环脂肽生物表面活性剂溶解在多元醇或水与多元醇的混合溶剂中，得到表面活性剂溶液；将油性成分与表面活性剂溶液混合，得到胶状组合物，其中胶状组合物中环脂肽生物表面活性剂与磷脂的质量比为 0.25 或以上。
• Amine-containing transfection reagents and methods for making and using same
  申请人：LIFE TECHNOLOGIES CORPORATION

  公开号：US10406237B2

  公开（公告）日：2019-09-10

  There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.

  本文提供了新型含胺转染化合物及其制造和使用方法。这些化合物通常是通过伯胺与不饱和化合物反应得到的。本文还提供了使用含胺转染化合物与其他化合物结合制成的转染复合物，以封装核酸等生物活性物质。还描述了使用转染复合物在体内或体外递送生物活性剂的方法。与本领域已知的类似转染化合物相比，本发明的转染复合物具有很高的效力，因此能以相对较低的剂量有效地调节生物活性。
• Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis
  申请人：CURADIGM SAS

  公开号：US10765632B2

  公开（公告）日：2020-09-08

  The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest effectiveness in therapy, prophylaxis or diagnosis. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.

  本发明涉及一种药物组合物，该组合物包含(i)至少一种生物相容性纳米粒子和(ii)至少一种包含至少一种药物化合物的载体的组合，用于给需要这种药物化合物的受试者给药，其中至少一种生物相容性纳米粒子和至少一种包含药物化合物的载体的组合增强了相关化合物在治疗、预防或诊断中的有效性。本发明还涉及这样一种组合物，该组合物用于给需要药物化合物的受试者施用药物化合物，其中至少一种生物相容性纳米粒子和至少一种包含至少一种药物化合物的载体将分别给需要所述药物化合物的受试者施用，通常彼此相隔 5 分钟以上至 72 小时左右。
• Nanoalum particles comprising a PAA sizing agent
  申请人：Infectious Disease Research Institute

  公开号：US11173126B2

  公开（公告）日：2021-11-16

  Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

  本文提供的纳米铝颗粒由一种铝盐和一种施胶剂组成，其中颗粒的尺寸范围为约 1 纳米至 450 纳米。这种纳米铝颗粒是稳定的，可在装瓶前进行终端灭菌步骤。此外，还提供了包含纳米铝颗粒的组合物以及纳米铝颗粒的制造和使用方法。